UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to_________ Commission File Number: 001-01011 CVS HEALTH CORPORATION (Exact name of registrant as specified in its charter) Delaware 05-0494040 (Sta ...

CVS Health Corporation (NYSE:CVS) Q4 2022 Earnings Conference Call February 8, 2023 8:00 AM ET Company Participants Tom Cowhey - Senior Vice President, Capital Markets Karen Lynch - President and Chief Executive Officer Shawn Guertin - Executive Vice President and Chief Financial Officer Mike Pykosz - Chairman, Chief Executive Officer and Co-Founder, Oak Street Health Daniel Finke - President, Healthcare Benefits Michelle Peluso - Chief Customer Officer and Retail Co-President Prem Shah - Chief Pharmacy Off ...

FOURTH QUARTER 2022 Earnings conference call February 8, 2023 KAREN S. LYNCH President ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to_________ Commission file number: 001-01011 CVS HEALTH CORPORATION (Exact name of registrant as specified in its charter) Delaware 05-0494040 (State or ...

Oak Street Health, Inc J.P. Morgan Healthcare Conference Disclaimer The presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements include statements regarding Oak Street Health, Inc.’s (the “Company”) future growth and our financial outlook for the fiscal year 2023. Forwar ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to_________ Commission File Number: 001-01011 ♥CVSHealth CVS HEALTH CORPORATION (Exact name of registrant as specified in its charter) Delaware ...

CVS Health Corporation (NYSE:CVS) Q2 2022 Earnings Conference Call August 3, 2022 8:00 AM ET Company Participants Larry McGrath - Senior Vice President Business Development and Investor Relations | Karen Lynch - President and Chief Executive Officer Shawn Guertin - Executive Vice President and Chief Financial Officer Alan Lotvin - President, Pharmacy Services Dan Finke - President, Healthcare Benefits Michelle Peluso - Executive Vice President. Chief Customer Officer and Co-President, Retail Prem Shah - Exe ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to_________ Commission File Number: 001-01011 ♥CVSHealth CVS HEALTH CORPORATION (Exact name of registrant as specified in its charter) Delaware 05-04 ...

CVS Health Corporation (NYSE:CVS) Q1 2022 Earnings Conference Call May 4, 2022 8:00 AM ET Company Participants Tom Cowhey - Senior Vice President, Capital Markets Karen Lynch - President and Chief Executive Officer Shawn Guertin - Executive Vice President and Chief Financial Officer Jon Roberts - Executive Vice President and Chief Operating Officer Alan Lotvin - President, Pharmacy Services Dan Finke - President, Healthcare Benefits Conference Call Participants Lisa Gill - JPMorgan Ricky Goldwasser - Morgan ...

Revenue Growth - Total revenues increased by $7.7 billion, or 11.2%, to $76.826 billion for the three months ended March 31, 2022, compared to the prior year, driven by growth across all segments [148]. - Total revenues increased by $2.6 billion, or 12.8%, to $23.1 billion for the three months ended March 31, 2022, compared to the prior year [162]. - Total revenues for the Pharmacy Services segment increased by $3.1 billion, or 8.6%, to $39.5 billion for the three months ended March 31, 2022, driven by increased pharmacy claims volume and brand inflation [171]. - Total revenues for the Retail/LTC segment increased by $2.1 billion, or 9.2%, to $25.4 billion for the three months ended March 31, 2022, driven by increased prescription and front store volume [179]. Premiums and Membership - Premiums rose by $2.671 billion, or 14.1%, to $21.631 billion, while product revenues increased by $5.135 billion, or 10.8%, to $52.522 billion [147]. - Premium revenues rose to $21.6 billion, a 14.1% increase from $18.9 billion in the same period last year [160]. - Total medical membership reached 24.522 million as of March 31, 2022, an increase from 23.626 million a year earlier [166]. - Medical membership increased by 674,000 members to 24.5 million as of March 31, 2022, compared to December 31, 2021, reflecting growth across all product lines [167]. Operating Income and Expenses - Operating income decreased by $87 million, or 2.4%, to $3.490 billion, primarily due to a $484 million legal settlement accrual related to opioid claims [150]. - Operating expenses increased by $954 million, or 10.7%, to $9.876 billion, with operating expenses as a percentage of total revenues remaining consistent at 12.9% [149]. - Adjusted operating income decreased slightly to $1.751 billion in Q1 2022, down from $1.782 billion in Q1 2021, primarily due to net realized capital losses [165]. - Operating expenses increased by $305 million, or 9.1%, to $3.651 billion in Q1 2022, driven by business growth [164]. - Operating income for the Health Care Benefits segment was $1.409 billion, a 2.1% increase from $1.380 billion in the same period last year [160]. Tax and Legal Matters - The effective income tax rate decreased to 21.5% for the three months ended March 31, 2022, compared to 25.1% for the same period in 2021 [153]. - The legal settlement accrual related to opioid claims amounted to $484 million, to be paid over 18 years, impacting the Corporate/Other segment [159]. Market and Economic Conditions - The Company continues to face uncertainties related to the COVID-19 pandemic, which may adversely impact its businesses and financial condition [143]. - The Company expects continued competitive pressures in the PBM industry to impact adjusted operating income due to larger portions of rebates shared with clients [173]. - Forward-looking statements are subject to significant risks and uncertainties that could cause actual results to differ materially [204]. - There is no assurance that the company has identified all risks affecting its business [204]. Cash and Investments - Net cash provided by operating activities increased by $671 million in the three months ended March 31, 2022, compared to the prior year, due to timing of payments [191]. - The Company had approximately $8.4 billion in cash and cash equivalents as of March 31, 2022, with about $3.0 billion held by the parent company or nonrestricted subsidiaries [189]. - During the three months ended March 31, 2022, the Company repurchased approximately 19.1 million shares of common stock for approximately $2.0 billion [197]. - The Company maintains a $2.0 billion, five-year unsecured back-up revolving credit facility, with no borrowings outstanding as of March 31, 2022 [192]. Pharmacy Services Performance - The Pharmacy Services segment anticipates continued growth in specialty pharmacy and improvements in purchasing economics, despite client price pressures [143]. - Total pharmacy claims processed increased by 5.5% on a 30-day equivalent basis for the three months ended March 31, 2022, excluding the impact of COVID-19 vaccinations [174]. - The generic dispensing rate for the Pharmacy Services segment decreased to 87.7% for the three months ended March 31, 2022, down from 88.1% in the prior year, primarily due to an increase in brand prescriptions [175]. - Adjusted operating income for the Pharmacy Services segment rose by $129 million, or 8.6%, to $1.636 billion for the three months ended March 31, 2022, primarily due to improved purchasing economics [173]. Retail Performance - Pharmacy same store sales increased by 10.1% for the three months ended March 31, 2022, primarily due to a 6.1% increase in pharmacy same store prescription volume [179]. - Front store same store sales increased by 13.2% in the three months ended March 31, 2022, compared to the prior year, driven by strong consumer health sales, including COVID-19 OTC test kits [180]. - Adjusted operating income rose by $211 million, or 15.1%, in the three months ended March 31, 2022, mainly due to increased prescription and front store volume [182].